Immunotherapy drug pembrolizumab improves outcomes for …
13 hours ago · The findings, published today in The Lancet, establish pembrolizumab as a new option for patients with this disease. "Soft tissue sarcoma is a rare and complex disease with over 50 different ...
FDA approves pembrolizumab with chemotherapy for …
On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or ...
Pembrolizumab plus Chemotherapy in Advanced Triple ...
Jul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
Adjuvant Keytruda Improves Kidney Cancer Survival - NCI
May 21, 2024 · Pembrolizumab (Keytruda) treatment after surgery helped people with clear-cell renal cell carcinoma live longer in a large trial—a first for this cancer.
FDA approves pembrolizumab for high-risk early-stage ...
On July 26, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy...
FDA approves pembrolizumab with chemotherapy ...
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of...
Clinical trial shows immunotherapy drug pembrolizumab …
1 day ago · The findings, published in The Lancet, establish pembrolizumab as a new option for patients with this disease. "Soft tissue sarcoma is a rare and complex disease with over 50 different subtypes ...
FDA Approves KEYTRUDA® (pembrolizumab) for ... - Merck
Jul 27, 2021 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Save. July 27, 2021 6:30 am ET.
FDA Approves Merck's KEYTRUDA® (pembrolizumab)
Nov 16, 2023 · Selected KEYTRUDA ® (pembrolizumab) Indications in the U.S. Gastric Cancer. KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
May 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.